Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer

Arigami,Takaaki; Uenosono,Yoshikazu; Ishigami,Sumiya; Yanagita,Shigehiro; Hagihara,Takahiko; Haraguchi,Naoto; Matsushita,Daisuke; Hirahara,Tetsushi; Okumura,Hiroshi; Uchikado,Yasuto; Nakajo,Akihiro; Hokita,Shuichi; Natsugoe,Shoji

doi:10.3892/or.2013.2775

Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer

Authors:
- Takaaki Arigami
- Yoshikazu Uenosono
- Sumiya Ishigami
- Shigehiro Yanagita
- Takahiko Hagihara
- Naoto Haraguchi
- Daisuke Matsushita
- Tetsushi Hirahara
- Hiroshi Okumura
- Yasuto Uchikado
- Akihiro Nakajo
- Shuichi Hokita
- Shoji Natsugoe
View Affiliations

Affiliations: Department of Digestive Surgery, Breast and Thyroid Surgery, Field of Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Molecular Frontier Surgery, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Department of Surgery, Jiaikai Imamura Hospital, Kagoshima, Japan
Published online on: October 1, 2013 https://doi.org/10.3892/or.2013.2775
Pages: 2838-2844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stanniocalcin 2 (STC2) is a glycoprotein hormone that plays an important role in calcium and phosphate homeostasis. Furthermore, recent studies have demonstrated that STC2 expression in the primary site is correlated with tumor progression in several types of malignancies. However, few reports have investigated the clinical significance of STC2 expression in the blood of patients with gastric cancer. Therefore, we examined STC2 expression as a molecular blood marker for detection of circulating tumor cells (CTCs) and assessed the relationship between STC2 expression and clinicopathological features including prognosis in patients with gastric cancer. Quantitative PCR assay was used to assess STC2 mRNA expression in 4 gastric cancer cell lines and in blood specimens from 93 patients with gastric cancer and 22 healthy volunteers. The numbers of STC2 mRNA copies were significantly higher in the gastric cancer cell lines and in blood from patients with gastric cancer than in blood from healthy volunteers (P=0.0002 and P=0.01, respectively). STC2 expression was positive in 43 (46.2%) of the 93 patients with gastric cancer, and its expression was significantly correlated with age, depth of tumor invasion, lymph node metastasis, stage and venous invasion (P=0.023, P=0.045, P=0.035, P=0.007 and P=0.027, respectively). The 5-year survival rate was significantly lower in patients with STC2 expression compared to patients without STC2 expression (P=0.014). Our results indicate that STC2 could be a useful molecular blood marker for predicting tumor progression by monitoring CTCs in patients with gastric cancer.

View Figures

View References

1	Statistics and Information Department, Ministry of Health, Labour, and Welfare. Vital Statistics of Japan 2004. Tokyo: Health and Welfare Statistics Association; 2006
2	Katanoda K and Yako-Suketomo H: Comparison of time trends in stomach cancer incidence (1973–2002) in Asia, from Cancer Incidence in Five Continents, Vols IV–IX. Jpn J Clin Oncol. 39:71–72. 2009.
3	Li ZX and Kaminishi M: A comparison of gastric cancer between Japan and China. Gastric Cancer. 12:52–53. 2009. View Article : Google Scholar : PubMed/NCBI
4	Lee H, Yun WK, Min BH, et al: A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc. 25:1985–1993. 2011. View Article : Google Scholar : PubMed/NCBI
5	Maehara Y, Orita H, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D and Sugimachi K: Predictors of lymph node metastasis in early gastric cancer. Br J Surg. 79:245–247. 1992. View Article : Google Scholar : PubMed/NCBI
6	Cai J, Ikeguchi M, Maeta M and Kaibara N: Micrometastasis in lymph nodes and microinvasion of the muscularis propria in primary lesions of submucosal gastric cancer. Surgery. 127:32–39. 2000. View Article : Google Scholar : PubMed/NCBI
7	Kim DY, Joo JK, Ryu SY, Kim YJ and Kim SK: Factors related to lymph node metastasis and surgical strategy used to treat early gastric carcinoma. World J Gastroenterol. 10:737–740. 2004.PubMed/NCBI
8	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
9	Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR and Reddel RR: A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 112:241–247. 1995. View Article : Google Scholar : PubMed/NCBI
10	Chang AC, Jeffrey KJ, Tokutake Y, et al: Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics. 47:393–398. 1998. View Article : Google Scholar : PubMed/NCBI
11	Wagner GF, Jaworski EM and Haddad M: Stanniocalcin in the seawater salmon: structure, function, and regulation. Am J Physiol. 274:R1177–R1185. 1998.PubMed/NCBI
12	Chang AC and Reddel RR: Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI
13	Ishibashi K and Imai M: Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol. 282:F367–F375. 2002. View Article : Google Scholar : PubMed/NCBI
14	Chang AC, Jellinek DA and Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer. 10:359–373. 2003. View Article : Google Scholar : PubMed/NCBI
15	Law AY and Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
16	Law AY and Wong CK: Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 316:3425–3434. 2010. View Article : Google Scholar : PubMed/NCBI
17	Bouras T, Southey MC, Chang AC, et al: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62:1289–1295. 2002.
18	Meyer HA, Tölle A, Jung M, et al: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol. 55:669–678. 2009. View Article : Google Scholar : PubMed/NCBI
19	Tamura K, Furihata M, Chung SY, et al: Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 100:914–919. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ieta K, Tanaka F, Yokobori T, et al: Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 125:926–931. 2009.
21	Volland S, Kugler W, Schweigerer L, Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer. 125:2049–2057. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yokobori T, Mimori K, Ishii H, et al: Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol. 17:2601–2607. 2010.
23	Kita Y, Mimori K, Iwatsuki M, et al: STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol. 18:261–272. 2011. View Article : Google Scholar
24	Arigami T, Natsugoe S, Uenosono Y, et al: Lymphatic invasion using D2–40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer. 93:688–693. 2005.
25	Arigami T, Natsugoe S, Uenosono Y, et al: Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg. 243:341–347. 2006. View Article : Google Scholar
26	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 6492010
27	Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R and Morton DL: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60:2253–2257. 2000.PubMed/NCBI
28	Miyazono F, Natsugoe S, Takao S, et al: Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg. 233:189–194. 2001. View Article : Google Scholar : PubMed/NCBI
29	Uen YH, Lin SR, Wu DC, et al: Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg. 246:1040–1046. 2007. View Article : Google Scholar : PubMed/NCBI
30	Ignatiadis M, Kallergi G, Ntoulia M, et al: Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600. 2008. View Article : Google Scholar
31	Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
32	Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008. View Article : Google Scholar : PubMed/NCBI
33	Krebs MG, Sloane R, Priest L, et al: Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI